Vaccines for an influenza pandemic: scientific and political challenges

Lars R. Haaheim

Influenza Centre, Section for Microbiology and Immunology, The Gade Institute, University of Bergen, Bergen, Norway.

Correspondence: Lars R. Haaheim, Influenza Centre, Section for Microbiology and Immunology, The Gade Institute, Armauer Hansen Building, Haukeland University Hospital, University of Bergen, N-5021 Bergen, Norway. Email: lars.haaheim@gades.uib.no

Accepted 1 May 2007.

Introduction

It is now nearly 40 years since the world’s last influenza pandemic. The 1997 Hong Kong incident of H5N1 avian influenza virus with associated human infections and death of six of the 18 confirmed cases raised a worldwide concern that a new pandemic was imminent. This episode showed unequivocally for the first time that avian influenza could be transmitted from infected poultry to man and cause serious systemic illness and death. The reappearance of highly pathogenic H5N1 in poultry in 2003, and the subsequent zoonotic cases in Asia, Europe and Africa have heightened the perceived risk of a pandemic. So far only limited human-to-human spread has been convincingly documented in a few cases.\(^1,2\) Although the apparent case-fatality rate is extremely high (approximately 60%), it may be an overestimate as less severe clinical cases may have gone unnoticed, although it has been claimed that this may not be the case.\(^3\) With close to 300 reported human cases of H5N1 avian influenza since late 2003, the situation today is causing alarm.\(^4\) The virus is genetically unstable and has evolved as a number of distinct genetic and antigenic clusters, complicating the selection of strains for clinical trials.\(^5-7\) In addition, the host range appears to have widened.\(^8\) Moreover, a small number of human cases of H9N2 in Hong Kong and China, and in recent years zoonoses with the H7 subtype have also raised concern, especially as limited inter-human spread has been documented.\(^9,10\)

To initiate infection the haemagglutinin (HA) of avian influenza viruses preferentially binds to epithelial cell sialic acid receptors with a terminal \(\alpha\)-2,3-galactose residue, whereas human strains prefer an \(\alpha\)-2,6-galactose linkage. It has now been reported that avian receptors can be found only in the lower respiratory tract in man, possibly explaining why zoonotic cases up until now have been few.\(^11-13\) Structural studies have demonstrated that just one or two amino acid substitutions at the receptor-binding region of the HA could change the receptor preference, and this has been seen in the case of occasional isolates of H5N1 viruses from human cases.\(^14\) The adaptation of avian influenza to the terminal \(\alpha\)-2,6-galactose receptor is presumably the first of several steps in the transition to a pandemic virus followed by others, for example, involving the NS1 and polymerase genes adapting the virus to efficient replication in human cells, and facilitating sustained human-to-human spread.\(^15\)
**Pandemic vaccines**

About half a century’s use of inactivated vaccine for seasonal influenza has provided clear evidence that serum antibodies against the HA antigen are associated with protection against illness and death. The current global annual vaccine output is approximately 350 million doses of trivalent doses containing $15\mu g$ HA of each strain and egg-based production cannot easily be scaled up in an emergency, as access to quality-assured embryonated hens’ eggs cannot be secured on short notice. Vaccine production based on cell culture is both easier to scale up and has the potential to maintain the genetic and antigenic authenticity of the seed virus, something which may be lost during growth in eggs.

This article will discuss some of the recent human clinical trials and for the most part will not refer to animal studies. Table 1 shows an overview of clinical trials currently under way or recently completed. As of 17 October 2006, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) listed 37 trials relevant for pandemic preparedness. It should be noted that not all trials are registered in this particular database (http://www.ifpma.org/Influenza/index.aspx?42). The greatest recent interest has been on vaccines for H5 influenza both because of the zoonotic outbreaks and in view of early studies, which indicated that the H5 HA is poorly immunogenic in man.

**Subvirion vaccines**

Currently the great majority of vaccines against seasonal influenza are subvirion vaccines, either split-product or purified surface antigen. Trials using non-adjuvanted egg-grown subvirion H5N1 vaccine or recombinant H5 HA both demonstrated that very high antigen doses ($90\mu g$ HA) given twice were required to elicit a reasonable immune response. For the egg-grown vaccine such high doses are clearly unacceptable in view of the difficulty of satisfying a pandemic demand. However, the well-tolerated recombinant protein vaccine, probably as an adjuvanted or virosomal formulation, offers some promise as scale-up procedures for recombinant proteins are considered far more feasible than egg-grown or even cell-grown vaccine production.

**Adjuvanted vaccines**

The use of adjuvants will most certainly be required to obtain satisfactory responses at acceptable antigen levels. Adjuvants have so far been used in 30 of the 34 inactivated virus vaccine trials registered by the IFPMA, mostly using non-proprietary aluminium salts. Overall, whole virus vaccines appear to perform better than subvirion vaccines when formulated with aluminium adjuvants. In a study using two doses of a putative pandemic vaccine containing H2N2 whole virus adjuvanted with alum it was shown that as little as $1.9\mu g$ HA gave a seroprotection rate of 82% in immunologically naive subjects, compared to 98% for a standard split and non-adjuvanted $15\mu g$ HA vaccine. Similar results were obtained for an H9N2 vaccine. When the same H9 subtype was used in a two-dose clinical study with non-adjuvanted whole or split vaccines, the whole virus formulation performed slightly better. However, this has not been the case with H5 antigens.

While a clinical trial with two doses of an alum-adjuvanted H5N1 whole virus vaccine containing $10\mu g$ HA satisfied the CHMP requirements for licensure, a split alum-

---

**Table 1. Overview of clinical trials of pandemic vaccines underway or recently completed**

| Strain | No. trials | Inactivated | Live, attenuated | Substrate | Adjuvanted |
|--------|------------|-------------|-----------------|-----------|------------|
|        |            | Whole* | Split | Surface* | Egg | Cell | Yes | No† |
| H5N1   | 25         | 7     | 11   | 5       | 2   | 21   | 4   | 20   | 5   |
| H5N3   | 2          | –     | –    | 2       | –   | 2    | –   | 2    | –   |
| H9N2   | 6          | 4     | –    | 1       | 1   | 6    | –   | 5    | 1   |
| H7N7   | 1          | 1     | 1    | –       | –   | 1    | –   | 1    | –   |
| H7N1   | 1          | –     | –    | –       | –   | –    | 1   | 1    | –   |
| H2N2   | 1          | 1     | –    | –       | –   | 1    | –   | 1    | –   |
| M2     | 1          | –     | –    | 1       | –   | –    | 1   | 1    | –   |
| Sum    | 37         | 12    | 13   | 9       | 3   | 31   | 6   | 30   | 7   |

Summarized from data from the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), 17 October 2006. For further details, including the names of the vaccine companies, see the IFPMA Clinical Trials Portal (http://www.ifpma.org/Influenza/index.aspx?42). A recent Chinese trial with whole egg-grown alum-adjuvanted vaccine is not tabulated here, but is registered with the ClinicalTrials.gov (http://clinicaltrials.gov/show/NCT00356798).

*Virosomal vaccines are tabulated as ‘whole’ and the M2 vaccine as ‘surface’.
†Live vaccines would not be adjuvanted.
adjuvanted egg-grown H5N1 vaccine required two doses of 30 μg HA to satisfy the licensing requirements for seasonal influenza vaccines. Two European vaccine manufacturers have announced, but not yet formally published, their preliminary results from trials with adjuvanted H5N1 vaccines. One alum-adsorbed cell-grown whole virus vaccine was claimed to stimulate cross-reactive antibodies against a range of H5 variants after two doses of 3.8 μg HA. Another company has announced that a split-virus formulation of egg-grown H5N1 (3.8 μg HA) with a novel proprietary adjuvant gave protective levels of anti-HA antibodies in more than 80% of the subjects.

The proprietary MF59 adjuvant has been successfully used both for seasonal and for a candidate H5 pandemic vaccine based on the surface antigens from a non-pathogenic H5N3 duck strain. Two doses of an adjuvanted 7.5 μg HA vaccine and 30 μg HA of a non-adjuvanted formulation satisfied the CHMP licensing criteria when tested against a 1977 human H5N1 isolate. This cross-reactivity against a variant H5 strains is a particular useful quality and could offer a substantial benefit for an eventual pre-pandemic vaccine meant to prime the population in advance of a pandemic. An even more pronounced cross-reactivity was found after a third dose given 16 months after the second dose.

**Intradermal dosing**

Given the scarce availability of vaccine when the pandemic strikes, dose-sparing strategies using intradermal dosing of seasonal vaccines have been evaluated and have demonstrated that 20–30% of a standard 15 μg dose would give a satisfactory immune response and thus be a way to stretch a limited vaccine supply. However, it remains to be seen how this strategy will work when unprimed subjects are tested against a pandemic strain candidate. Furthermore, it is doubtful whether the more difficult intradermal injection procedure will be feasible in a mass-vaccination programme.

**Antigen delivery systems**

It is widely recognized that whole virion vaccines are more immunogenic than the split and subunit formulations. However, most seasonal influenza vaccines used today are not of the whole virus type. To generate better immune response against seasonal influenza, particularly among elderly subjects, trials using purified viral proteins in reconstituted virus-like particles have been completed with promising results.

Another approach has been the use of a ‘biovector’ for intranasal delivery. The formulation uses a biodhesive delivery system incorporating a lipid micro-micelle system carrying vaccine antigens and a modified *Escherichia coli* enterotoxin. In a clinical trial with such an intranasal trivalent vaccine containing 7.5 μg HA from influenza H3N2, H5N3 and B strains, the H5 antigen, in contrast to the H3 and B components, failed to induce significant levels of neutralizing serum antibodies, but at the same time elicited a substantial mucosal IgA response. While the vaccine was well tolerated, it only satisfied the CHMP regulatory requirements for the B component, whereas the 15 μg MF59 adjuvanted parenteral comparator passed the test for all strains. The longevity of the anti-H5 mucosal IgA response, and to what degree the H5 component elicited a long-lasting mucosal memory, remains to be evaluated.

**‘Universal’ vaccine?**

The vaccine industry has learned to cope with the challenge of updating the antigenic formulation of seasonal influenza vaccines. However, the need for annual vaccination and a close match between the antigens of the vaccine viruses is far from ideal. A vaccine not sensitive to antigenic drift in the HA of the circulating strains would therefore be a major breakthrough. This would even more important in the face of a pandemic where the exact antigenic nature of the new virus could not be anticipated, particularly if stockpiling pre-pandemic vaccine is contemplated. A broadly protecting vaccine is, therefore, highly desirable. While other antigens have been considered, the highly conserved trans-membrane M2 protein, the ion channel of influenza A, is a favoured candidate antigen. Immunity to M2 will not neutralize virus but rather reduce the clinical severity of the infection. The M2 protein in the virion itself is only poorly immunogenic. However, as the M2 is expressed on the surface of infected cells, it is a relevant target provided such an immune response could be initiated in the first place. To date several promising preclinical studies have been completed demonstrating a heterosubtypic response. A clinical trial in humans is now underway (Table 1).

**DNA vaccines**

The DNA vaccine concept should offer many advantages in a pandemic situation. This could be its rapid manufacturing process and scaling-up potential, its heat resistance and ease of strain adjustments, as well as presenting the immunogen in its authentic form and possibly also the ability to elicit a CTL response. A clinical trial with an influenza H3 DNA construct has been performed, and as little as 1 μg DNA satisfied one of the three CHMP criteria for serum antibody response, whereas all three requirements were met for the higher doses (2 and 4 μg) 8 weeks post-vaccination. A rapid vaccine response is especially important for a pandemic situation, and higher DNA dosages may be required to achieve this. However, the extent to which any previous H3 memory aided the DNA vaccine response is not known. Any planned large-scale use of DNA vaccines would certainly focus attention on the particular safety concerns raised.
regarding injecting nucleic acid material. That concern should be balanced against the public health implications of not offering immune prophylaxis of any kind.

Another cautionary note is also in place. Pigs vaccinated with a DNA construct containing the M2 gene sequence were not protected when challenged with live virus and suffered a more serious clinical outcome than the unvaccinated control animals. This could possibly be a consequence of an eventual Th1-biased immune response, contributing to the excessive inflammatory reaction in the challenged vaccinated animals.

Pre-pandemic ‘priming’

As the H5N1 strains continue to evolve, the selection of appropriate vaccine strains has become increasingly difficult. In view of the large dosages and repeated vaccinations required to fulfil current licensing requirements for currently registered inactivated vaccines, as well as the risk of not having a pandemic vaccine available in time, pre-pandemic priming has been proposed. It is promising that preliminary data from a recent clinical data have showed that individuals primed with an H5N1 clade 3 vaccine strain 8 years earlier, substantially improved the immune response to a subsequent H5N1 clade 1 vaccine when compared to immunologically naïve subjects. For a pandemic situation, the assumption is that a primed individual will, when infected with an antigenically variant pandemic virus (of the same subtype), generate a rapid cross-reactive immunity that will lessen the clinical impact.

Other scientific challenges

For reasons that have been inadequately determined, many contemporary vaccines for H5 influenza have not consistently elicited levels of circulating antibodies that will satisfy current licensing criteria. Live attenuated vaccines and M2-derived vaccine formulations will similarly fail to meet current antibody-based criteria. As field efficiency trials of pandemic vaccine candidates cannot be undertaken, we face a regulatory predicament. However, clinical trials with live attenuated H5N1 virus open up the possibility of undertaking controlled challenge studies in volunteers having been immunized with a candidate pandemic vaccine. This point was especially mentioned in the Sixth Framework Programme of the European Union, having specifically called for such challenge trials.

The respiratory distress syndrome and multiorgan failure frequently seen in H5N1 patients is sometimes attributed to the consequence of a ‘cytokine storm’ and said to resemble to clinical picture observed for many of the 1918–1919 pandemic victims. Whether this inflammatory dysregulation is a consequence of the host’s vigorous immune response or an effect of the rapidly replicating virus is not clear. If the eventual pandemic virus swiftly attacks the cells of the lower respiratory tract, there may be a risk of immunopathological events, potentially worsened if the offending pandemic virus should boost a CTL-memory induced by a pre-pandemic vaccine. It therefore raises the pertinent question whether a pandemic vaccine should aim at stimulating a cytotoxic response in addition to the required humoral response. There are suggestions that whole virus and virosomal vaccine formulations will stimulate a CTL response by way of fusion of the viral/virosomal and endosomal membranes, allowing the peptides also to be presented on MHC. While the M2 protein offers interesting possibilities as a vaccine antigen, some caution must be exercised in view of the harmful outcome experienced in a pig model when M2 was delivered using the DNA vaccination approach which induced both antibody and cell-mediated responses.

Political challenges

While there seems to be a consensus regarding the need for improving pandemic preparedness in general, and in particular for the rapid development of new vaccine strategies, progress has been slow. Who is going to pay for the basic and applied research efforts and for the clinical trials? While development of vaccines is clearly within the remit of what may be expected of the pharmaceutical industry, the threat of an imminent pandemic has made it clear that private–public partnerships, and possibly more public than private, will be required to speed up vaccine development.

Following the H5N1 events in Hong Kong in 1997, and the subsequent zoonotic cases since 2003, the scientific community and the pharmaceutical industry envisaged a much needed flow of fresh research and development grants to address the many unknowns regarding the virus itself and the many challenges of preparing an efficacious pandemic vaccine. However, with very few exceptions, the academia, research establishments and vaccine industry had to settle for meagre and sometimes no public support at all. The inability of the scientific community and industry to lobby for more substantial financial support is remarkable when only a fraction of what is financially needed has been earmarked for pandemic preparedness.

Faced with a pandemic, antiviral drugs (the adamantanes and neuraminidase inhibitors) could be used both prophylactically and therapeutically to alleviate the situation, provided that drug resistance does not make them redundant. However, the global production of neuraminidase inhibitors may be inadequate and also too expensive for most nations. The consensus is that a pandemic vaccine will be our best option. The influenza vaccine market is dominated...
by a small number of companies, most of them located in Europe, providing about 70% of the current global output of approximately 350 million trivalent doses of inactivated vaccine for seasonal influenza. For a pandemic scenario the industry will deliver too few doses too late, at least for the first pandemic wave. International sale and distribution of such a life-saving and scarce global commodity could be severely restricted or even prohibited by political interventions. Even if a fair distribution of vaccine between countries were agreed upon, the current industrial output would only cover a fraction of the soaring demand. As the equity dilemma is still unresolved, the WHO can only urge an increased use of seasonal influenza vaccine and call for new vaccine production facilities, so that the gap between global production capacity and the eventual pandemic surge will be lessened.

Remembering the 8000 SARS cases in 2003 and the resulting financial losses, the impact of an influenza pandemic on world trade could be dramatically more disruptive. The globalized industry today operates with extremely small stocks of spare parts and/or raw materials, depending on a ‘just in time’ and uninterrupted flow of domestic and especially international goods to keep the industrial wheels turning. In this respect, the trade situation during the last pandemic in 1968 was strikingly different. Today, one can only assume that an eventual global financial depression and stagnant trade would severely obstruct any ad hoc emergency attempts by governments and industry to procure essential goods both during and also after the pandemic. The financial sequel would itself have a negative effect on global health.

References

1 Anonymous. Epidemiology of WHO-confirmed human cases of avian influenza A(H5N1) infection. Wkly Epidemiol Rec 2006;81:249–257.
2 Kandun IN, Wiribono H, Sedyaningish ER et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med 2006;355:2186–2194.
3 Vong S, Coghlan B, Mardy S et al. Low frequency of poultry-to-human H5N1 virus transmission, southern Cambodia, 2005. Emerg Infect Dis 2006;12:1542–1547.
4 The Writing Committee of the World Health Organization (WHO). Consultation on human influenza A/H5. Avian influenza A (H5 N1) infection in humans. N Engl J Med 2005;353:1374–1385.
5 Chen H, Smith GJD, Li K et al. Establishment of multiple sublineages of H5N1 influenza virus in Asia: implications for pandemic control. Proc Natl Acad Sci U S A 2006;103:2845–2850.
6 Smith GJD, Fan XH, Wang J et al. Emergence and predominance of an H5N1 influenza variant in China. Proc Natl Acad Sci USA 2006;103:16936–16941.
7 WHO. Antigenic and genetic characteristics of H5N1 viruses and candidate H5 N1 vaccine viruses developed for potential use as pandemic vaccines. http://www.who.int/csr/avian_influenza/guidelines/recommendationvaccine.pdf [accessed on 18 August 2006].
8 Report of a WHO Working Group. Influenza research at the human and animal interface. WHO/CDS/EPR/GIP/2006.3. WHO, Geneva, Switzerland, 21–22 September 2006. http://www.who.int/entity/csr/resources/publications/influenza/WHO_CDS_EPR_GIP_2006_3C.pdf.
9 Koopmans M, Wilbrink B, Conyn M et al. Transmission of H7 N7 avian influenza virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 2004;363:587–593.
10 Puzzelli S, Di Trani L, Fabiani C et al. Serological analysis of serum samples from humans exposed to avian H7 influenza viruses in Italy between 1999 and 2003. J Infect Dis 2005;192:1318–1322.
11 van Riel D, Munster VJ, de Wit E et al. H5N1 virus attachment to lower respiratory tract. Science 2006;312:399.
12 Shinya K, Ebina M, Yamada S, Ono M, Kasai N, Kawao Y. Influenza virus receptors in the human airway. Nature 2006;440:435–436.
13 Stevens J, Blix D, Tumpey TM, Taubenberger JK, Poulson JC, Wilson IA. Structure and receptor specificity from an H5N1 influenza virus. Science 2006;312:404–410.
14 Yamada S, Suzuki Y, Suzuki T et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature 2004;444:378–382.
15 Krug RM. Clues to the virulence of H5N1 viruses in humans. Science 2006;311:1562–1563.
16 Cox NJ, Brokstad KA, Ogra PL. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004;59:1–15 (Review).
17 Fedson DS. Vaccine development for an imminent pandemic. Hum Vaccin 2006;2:38–42.
18 Oxford JS, Manuguerra C, Kistner O et al. A new European perspective of influenza pandemic planning with a particular focus on the role of mammalian cell culture vaccines. Vaccine 2000;23:5440–5449.
19 Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirus influenza A (H5N1) vaccine. N Engl J Med 2006;354:1343–1351.
20 Treanor JJ, Wilkinson BE, Masseoud F et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001;19:1732–1737.
21 Hohm N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminium-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res 2004;103:163–171.
22 Hohm N, Engelmann H, Kuenzel W, Neumeier E, Sanger R. Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines. Med Microbiol Immunol 2002;191:203–208.
23 Stephenson I, Nicholson KG, Gloek R et al. Safety and antigenicity of whole virus and subunit influenza A (Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 2003;362:1959–1966.
24 Lin J, Zhang J, Dong X et al. Safety and immunogenicity of an inactivated adjuvanted whole-virus influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006;368:991–997.
25 Bresson J-L, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virus influenza A (Vietnam/1994/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006;367:1657–1664.
26 Baxter. Baxter Press Release: Baxter Announces Safety and Immunogenicity Results from Phase I/II Clinical Trial of Cell-Based Candidate H5N1 Pandemic Vaccine. http://www.baxter.com/about_baxter/news_room/news_releases/2006/10-04-06-h5n1_trial.html [4 October 2006].
GlaxoSmithKline: GlaxoSmithKline Press Release: GSK Reports Significant Advance in H5 N1 Pandemic Flu Vaccine Programme. http://www.gsk.com/ControllerServlet?appId=4&pageId=402&newsid=868 [26 July 2006].

Del Giudice G, Hilbert AK, Bugarini R et al. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006;24:3063–3065.

Nicholson KG, Colegate AE, Podda A et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001;357:1937–1943.

Stephenson I, Bugarini R, Nicholson KG et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005;191:1210–1215.

Auewarakul P, Kostapanon U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P. Antibody responses after dose-sparing intradermal influenza vaccination. Vaccine 2007;25:659–663.

Belshe RB, Newman FK, Joan Cannon J et al. Serum antibody responses after intradermal vaccination against influenza. N Engl J Med 2004;351:2295–2301.

de Bruijn IA, Nauta J, Gerez L, Palache AM. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res 2004;103:139–145.

de Bruijn IA, Nauta J, Cramer WCM, Gerez L, Palache AM. Clinical experience with inactivated, virosomal influenza vaccine. Vaccine 2004;351:2295–2301.

de Bruijn IA, Nauta J, Gerez L, Palache AM. Virosomal influenza vaccine: a safe and effective influenza vaccine with high efficacy in elderly and subjects with low pre-vaccination antibody titers. Virus Res 2004;103:139–145.

Huckriede A, Bungener L, Stegmann T et al. The virosoe concept for influenza vaccines. Vaccine 2005;23(1):26–38 (Review).

Stephenson I, Zambon MC, Rudin A et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxicogenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006;80:4962–4970.

Neirynck S, Deroo T, Saelsens X, Vanlandschoot P, Min Jou W, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 1999;5:1157–1163.

Ernst WA, Kim HJ, Tumpey TM et al. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2004;22:5158–5168.

Kaiser J. A one-size-fits-all flu vaccine? Science 2006;312:380–382.

Drape RJ, Macklin MD, Barr LJ, Jones S, Haynes JR, Dean HJ. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006;24:4475–4481.

Heinen PP, Rijsewijk FA, de Boer-Luijte EA, Bianchi ATJ. Vaccination of pigs with DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 2002;83:1851–1859.

Montomoli E, Manini I. Pre-emptive vaccination against pandemic influenza virus. Vaccine 2007,25:1921–1922.

Subbarao K, Murphy BR, Fauci AS. Development of effective vaccines against pandemic influenza. Immunity 2006;24:5–9.

Stephenson I, Nicholson KG, Colegate A et al. Boosting immunity to influenza H5 N1 with MF59-adjuvanted H5 N3 A/Duck/Singapore/97 vaccine in a primed human population. Vaccine 2003;21:1687–1693.

Goji NA, Nolan C, Hill H et al. Immune Responses of Healthy Subjects to a Single Dose of Intramuscular Inactivated Influenza A/Vietnam/1203/2004 (H5N1) Vaccine after Priming with an Antigenic Variant. 44th IDSA abstract LB-4. Toronto: Infectious Diseases Society of America, 2006.

Trenar J, Wright PF. Immune correlates of protection against influenza in the human challenge model. Dev Biol (Basel) 2003;115:97–104.

Call Identifier FP6–2005–SSP-5B-INFLUENZA. http://cordis.europa.eu/fp6/dc/index.cfm?fuseaction=USERSite.IP6Details&CallPage&call_id=269; [accessed 29 March 2007].

Seo SH, Hoffmann E, Webster R. Lethal H5N1 influenza viruses escape host anti-viral cytokine responses. Nat Med 2002;8:950–954.

Chan MCW, Cheung CY, Chui WH et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005;6:135.

de Jong MD, Simmons CP, Thanh TT et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinaemia. Nat Med 2006;12:1203–1207.

Gronvall GK, Borio L. Removing barriers to global pandemic influenza vaccination. Biosecur Bioterror 2006;4:168–175.

Daems R, Giudice G, Rappuoli R. Anticipating crisis: towards a pandemic influenza vaccine. TrendsMed/DocsPDF06/863.pdf [accessed 20 September 2006].

Levine R. A cure for the Asian flu. Biosecur Bioterror 2006;4:228–230.

Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy 2005;26:4–29.

WHO. Global pandemic influenza plan to increase vaccine supply. WHO/IVB/06.13. September 2006, www.who.int/vaccine-documents/DocsPDF06/863.pdf [accessed 20 September 2006].

Osterholm MT. Preparing for the next pandemic. Foreign Aff 2005;84:24–37.